Company news
Alvotech news in 2025
Alvotech's news releases, calls and decks from 2025, newest first.
Alvotech Secures Term Loan Facility of USD 100 Million
December 30, 2025
Alvotech’s Financial Calendar for 2026
December 21, 2025
Alvotech announces European launch of first-in-market biosimilar to Simponi® (golimumab) globally by partner Advanz Pharma
December 21, 2025
Alvotech and Teva Secure U.S. Settlement Date for AVT06, a Proposed Biosimilar to Eylea®
December 18, 2025
Alvotech Successfully Places USD 108 Million Senior Unsecured Convertible Bonds in a Significantly Oversubscribed Offering
December 16, 2025
Alvotech Launches $100 Million Senior Unsecured Convertible Bond Offering to Continue Strong Investment in R&D, Support Manufacturing, Global Product Launches and Enhance Liquidity Position, reaffirms 2025 outlook and provides 2026 guidance
December 15, 2025
Alvotech Announces Approval of AVT03, a Biosimilar to Prolia® and Xgeva® (denosumab) in the European Economic Area
November 23, 2025
Alvotech and Advanz Pharma Receive Marketing Approval Across the European Economic Area for Gobivaz®, a First-in-Market Biosimilar to Simponi® (golimumab)
November 19, 2025
Alvotech Reports Results for the First Nine Months of 2025 and Provides a Business Update
November 11, 2025
UK High Court Rules in Favor of Alvotech Paving Way for Manufacture and Market Entry of AVT06, biosimilar to Eylea® (aflibercept)
November 9, 2025
UK High Court Rules in Favor of Alvotech Paving Way for Manufacture and Market Entry of AVT06, biosimilar to Eylea® (aflibercept)
November 9, 2025
Alvotech and Advanz Pharma Receive Marketing Authorisations for Gobivaz®, a Biosimilar to Simponi® (golimumab), from the MHRA
November 5, 2025
Alvotech Announces Webcast on November 13, 2025 to Report Financial Results for the First Nine Months of 2025 and Provide a Business Update
November 3, 2025
Alvotech Provides Update on the Status of U.S. Biologics License Application for AVT05
November 1, 2025
Alvotech Provides Update on the Status of U.S. Biologics License Application for AVT05
November 1, 2025
Alvotech Announces Changes in Global Business Development and Commercial Operations Team
October 21, 2025
Kashiv Biosciences Announces Submission of Biologics License Application to U.S. FDA and Acceptance of Market Authorization Application by European Medicines Agency for ADL-018, a Proposed Biosimilar to XOLAIR® (omalizumab)
October 5, 2025
European Marketing Application for AVT23, a Proposed Biosimilar to Xolair® (omalizumab), Accepted by the European Medicines Agency
October 5, 2025
European Medicines Agency Recommends Marketing Authorization of AVT03, Alvotech’s Proposed Biosimilar to Prolia® and Xgeva®
September 21, 2025
European Medicines Agency Recommends Marketing Approval of Gobivaz®, Alvotech’s Proposed Biosimilar to Simponi® (golimumab) with Advanz Pharma as Commercialization Partner
September 21, 2025
Alvotech Announces Marketing Approval in Japan of Three New Biosimilars
September 18, 2025
Alvotech Meets Investors and Participates in a Fireside Chat at the Morgan Stanley 23rd Annual Global Healthcare Conference in New York
September 3, 2025
Advanz Pharma and Alvotech receive European approval for Mynzepli®, Biosimilar to Eylea®
August 20, 2025
Alvotech appoints Patrik Ling as VP of Investor Relations Scandinavia
August 19, 2025
Alvotech Reports Results for the First Six Months of 2025 and Provides a Business Update
August 12, 2025
Alvotech Reports Results for the First Six Months of 2025 and Provides a Business Update
August 12, 2025
Alvotech Announces Webcast to Report Financial Results for the First Half of 2025 on August 14, 2025, at 8: 00 am EDT
August 5, 2025
Alvotech Appoints Linda Jónsdóttir as Chief Financial Officer
July 9, 2025
Alvotech Expands its Capacity in Assembly and Packaging with the Acquisition of Ivers-Lee Group in Switzerland
July 8, 2025
Alvotech Expands its Capacity in Assembly and Packaging with the Acquisition of Ivers-Lee in Switzerland
July 8, 2025
Notification for the purposes of article 13 of the Luxembourg law of 11 January 2008 on transparency requirements for issuers
July 2, 2025
Granting of Stock Options and Vesting of Restricted Share Units
June 30, 2025
Alvotech and Advanz Pharma Enter into European Supply and Commercialization Agreement for Biosimilar Candidate to Cimzia® (certolizumab pegol)
June 30, 2025
Alvotech’s Lenders Lower Interest on Senior Secured Term Loan Facility
June 25, 2025
Positive Top Line Results from Confirmatory Efficacy Study for Proposed Biosimilar to Xolair® (omalizumab)
June 24, 2025
Positive Top Line Results from Confirmatory Efficacy Study for Proposed Biosimilar to Xolair® (omalizumab)
June 24, 2025
Main Results of 2025 Annual and Extraordinary General Meeting
June 24, 2025
European Medicines Agency Recommends Market Approval of AVT06, Alvotech’s Proposed Biosimilar to Eylea® (aflibercept)
June 22, 2025
European Medicines Agency Recommends Market Approval of AVT06, Alvotech’s Proposed Biosimilar to Eylea® (aflibercept)
June 22, 2025
Alvotech’s Private Placement Completed with Delivery of SDRs and Shares to Investors
June 10, 2025
Alvotech’s Private Placement Completed with Delivery of SDRs and Shares to Investors
June 10, 2025
Alvotech Participates in the Goldman Sachs Global Healthcare Conference in Miami
June 5, 2025
Alvotech Meets Investors and Presents at the Goldman Sachs Global Healthcare Conference in Miami
June 5, 2025
Alvotech and Dr. Reddy’s Enter into Collaboration to Co-Develop Biosimilar Candidate to Keytruda® (pembrolizumab)
June 4, 2025
Alvotech intends to carry out a private placement of approximately 7.5 million SDRs and ordinary shares
June 3, 2025
Alvotech has carried out a private placement of 7,500,000 SDRs and ordinary shares at a price of SEK 100.00 per SDR and ISK 1320.83 per ordinary share, raising gross proceeds of SEK 750 million
June 3, 2025
Alvotech Completes Acquisition of Xbrane R&D Organization and biosimilar candidate to Cimzia®
June 3, 2025
Alvotech Meets Investors and Presents at the Jefferies Global Healthcare Conference 2025 in New York, NY
June 1, 2025
Alvotech and Advanz Pharma Extend Strategic Partnership to Commercialize Three Additional Biosimilars in Europe
May 27, 2025
Alvotech Annual General Meeting to be held June 25, 2025
May 25, 2025
Calls in 2025
Decks in 2025
- Q3 2025 Earnings Presentation
Earnings · 23 slides · Nov 13, 2025
- Q2 2025 Earnings Presentation
Earnings · 12 slides · Aug 14, 2025